News & Updates

Individuals at elevated cardiovascular disease risk (overweight/obese, increased blood pressure levels) may improve the duration and efficiency of their sleep through regular resistance exercise regimens, according to a study presented at the EPI Lifestyle Scientific Sessions 2022.

Rigorous monitoring is necessary among recipients of allogeneic haematopoietic stem cell transplantation (allo-HSCT) for the development of metabolic diseases, such as hypertension, diabetes, dyslipidaemia, and cardiovascular disease (CVD), suggests a recent study.

Subclinical hyperthyroidism (SHyper) does not independently correlate with major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), results of a study have shown.

Type 2 diabetes patients who use sodium-glucose cotransporter 2 inhibitors (SGLT2is) see no increase in the risk of fractures, a recent Korea study has found.

Individuals who consume a moderate amount of wine with meals may have a reduced risk of new-onset type 2 diabetes (T2D), according to a study presented at the EPI Lifestyle Scientific Sessions 2022.

Individuals with severe insulin-resistant diabetes (SIRD) appear to have the lowest physical fitness compared with other diabetes subgroups despite similar endothelial function across all cohorts, a study has shown. Moreover, those with severe autoimmune diabetes (SAID) have the lowest cardiovascular risk within the first year following diagnosis relative to other clusters.

In individuals with type 2 diabetes (T2D), greater variability in adiposity indices (BMI and waist circumference [WC]) was tied to increased risk of cardiovascular disease (CVD) outcomes and death – but an intensive weight loss programme mitigated this risk, a study suggests.

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalization for heart failure (hHF) and all-cause death in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease, reports a new study.

Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.